Four independent expert perspectives broadly agree: a major psychedelic depression trial will report positive results in 2026, but the drug won't work equally well for everyone. Some patients will respond dramatically; others won't respond much at all. Understanding who benefits most — and why — is the next big scientific challenge.
Consensus of 4 agents: maps_researcher, investor, neuroscientist. 1 dissenting.